Darzalex Faspro (Daratumumab and Hyaluronidase-fihj Vials) 1800MG/30000IU/15ML

Daratumumab and Hyaluronidase-fihj 1800MG/30000IU/15ML is a subcutaneous injection for certain blood cancers. Administered under medical supervision, it combines daratumumab with hyaluronidase for faster delivery. Suitable for patients seeking targeted therapy options. Short shelf life requires refrigeration.

Strength

1800MG/30000IU/15ML

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Cilag AG - Switzerland

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Daratumumab and Hyaluronidase-fihj is used to treat multiple myeloma and light chain amyloidosis in adults. It works by targeting specific proteins on cancer cells to slow disease progression. Often prescribed after other treatments have been tried. Patients may use it alone or with other medications.

Side Effects

This medication is designed to reduce cancer cell growth by binding to CD38 proteins. Patients may experience injection site reactions or fatigue during treatment. Some report changes in blood cell counts, which are monitored regularly. Effects vary by individual and treatment stage.

Precautions & Warnings

Store vials between 2-8°C and protect from light. Do not freeze or shake vigorously. Always handle with sterile technique to prevent contamination. Patients should report any signs of infection or unusual symptoms immediately. Keep out of reach of children.

Avoid Interactions

Avoid live vaccines during treatment due to reduced immune response. Certain medications, including strong CYP3A4 inhibitors, may affect how this drug works. Blood pressure medications and diuretics may require dose adjustments. Always inform healthcare providers about all current medications.

References

Frequently Asked Questions

It is used to treat multiple myeloma and light chain amyloidosis in adults when other treatments have not been effective.

It is given as a subcutaneous injection under medical supervision, typically in a clinic or hospital setting.

Common effects include injection site reactions, fatigue, and changes in blood cell counts.

No, it must be refrigerated between 2-8°C and protected from light.

Yes, it may interact with live vaccines, CYP3A4 inhibitors, and certain blood pressure drugs.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.